[Psychological changes in parkinsonian patients during L-DOPA, amantidine, and L-DOPA + IDC treatment (author's transl)].
D000547:Amantadine / Q000627:therapeutic use*; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001545:Benserazide / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D007980:Levodopa / Q000627:therapeutic use*; D008606:Mental Processes / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy*; D011581:Psychological Tests
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D006834:Hydrazines; D007980:Levodopa; D001545:Benserazide; D000547:Amantadine
Modificazioni psicologiche in parkinsoniani in corso di trattamenti farmacologici con L-DOPA, amantadina e L-DOPA + I.D.C